Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Master Transcription Regulators02:23

Master Transcription Regulators

8.1K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
8.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

5.1K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
5.1K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

582
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
582
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

400
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
400
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

21.3K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
21.3K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

2.1K
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Crossing the Halfway Point: Aptamer-Based, Highly Multiplexed Assay for the Assessment of the Proteome.

Journal of proteome research·2024
Same author

Magnetically Detected Protein Binding Using Spin-Labeled Slow Off-Rate Modified Aptamers.

ACS sensors·2023
Same author

Modified nucleotides may have enhanced early RNA catalysis.

Proceedings of the National Academy of Sciences of the United States of America·2020
Same author

Personalized medicine: something old, something new.

Personalized medicine·2018
Same author

Taking measure of personalized medicine: the proteome.

Personalized medicine·2018
Same author

Erratum: Connecting genetic risk to disease end points through the human blood plasma proteome.

Nature communications·2017

Related Experiment Video

Updated: Apr 18, 2026

TMT Sample Preparation for Proteomics Facility Submission and Subsequent Data Analysis
07:44

TMT Sample Preparation for Proteomics Facility Submission and Subsequent Data Analysis

Published on: June 8, 2020

13.6K

DTC-and-Me: Patient, Provider, Proteins and Regulators.

Fintan R Steele1, Larry Gold2

  • 1SomaLogic Inc., 2945 Wilderness Pl., Boulder, CO 80301, USA. fsteele@somalogic.com.

Journal of Personalized Medicine
|January 7, 2015
PubMed
Summary
This summary is machine-generated.

Personalized Direct-to-Consumer (DTC) genetic testing offers healthcare transformation potential but faces scientific validity and actionability challenges. A proposed approach aims to meet patient, provider, and regulatory needs.

More Related Videos

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.9K
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.8K

Related Experiment Videos

Last Updated: Apr 18, 2026

TMT Sample Preparation for Proteomics Facility Submission and Subsequent Data Analysis
07:44

TMT Sample Preparation for Proteomics Facility Submission and Subsequent Data Analysis

Published on: June 8, 2020

13.6K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.9K
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.8K

Area of Science:

  • Genomics
  • Healthcare Policy
  • Biotechnology

Background:

  • Direct-to-Consumer (DTC) genetic testing is rapidly evolving, presenting significant opportunities for personalized medicine.
  • The widespread adoption of DTC tests is hindered by challenges in ensuring scientific rigor and clinical utility.
  • Recent developments highlight the need for robust frameworks to govern DTC genetic information.

Purpose of the Study:

  • To explore the potential of personalized DTC genetic tests in transforming healthcare.
  • To address the critical challenges of scientific validity and medical actionability in DTC testing.
  • To propose a novel approach for DTC genetic testing that balances innovation with patient and regulatory needs.

Main Methods:

  • Review of recent events and trends in the DTC genetic testing market.
  • Analysis of the scientific and clinical considerations for DTC genetic test interpretation.
  • Development of a conceptual framework through a "thought experiment" for future DTC testing models.

Main Results:

  • The potential for DTC tests to personalize healthcare is substantial but currently limited by scientific and actionable data concerns.
  • Existing DTC testing models face scrutiny regarding data accuracy and clinical relevance.
  • A framework is proposed to enhance the trustworthiness and utility of DTC genetic information for all stakeholders.

Conclusions:

  • Personalized DTC genetic testing holds immense promise for revolutionizing healthcare delivery and economics.
  • Overcoming challenges in scientific soundness and medical actionability is crucial for realizing the full potential of DTC tests.
  • The proposed approach offers a pathway to align patient, provider, and regulatory expectations for DTC genetic testing.